Oncolytics Biotech Investor Presentation 2024 Pelareorep Cancer Immunotherapy

Oncolytics Biotech presents pelareorep, a systemically dosed immunotherapeutic agent delivering double-stranded RNA to stimulate anti-tumor immunity. The presentation covers robust clinical data in breast and pancreatic cancer, favorable safety profiles, and plans for registrational studies beginning in 2024, supported by collaborations with major pharma partners and Fast Track designations.